Bar chart shows HPV genotype frequency across tissue sites. The X-axis lists 65 HPV genotypes: A@number, B@number, and G@number. Y-axis shows the frequency. 'Most frequently detected HPV genotype' highlighted in blue bars.

#CutaneousSquamousCellCarcinoma in Asian organ transplant recipients and immunocompetent patients featured distinct distributions of 65 #HPV genotypes, with B-HPV showing the greatest site overlap.

ja.ma/4sUwf5a

History of Severe Sunburn Linked to Cutaneous Squamous Cell Carcinoma The researchers noted that the findings support the existing literature and suggest a connection between severe sunburns and CSCC that is similar to what is seen with basal cell carcinoma.

A history of painful, blistering, or severe #sunburn is linked with increased odds of developing #cutaneousSquamousCellCarcinoma. Published in @jamadermatology.com.

https://bit.ly/3M7FSfX

#CSCC #carcinoma

Regeneron's Libtayo stakes out new territory in skin cancer Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

#Regeneron #Libtayo #cemiplimab #skincancer #Squamouscellcarcinoma #checkpointinhibitor #FDA #cutaneoussquamouscellcarcinoma #CSCC #basalcellcarcinoma #nonsmallcelllungcancer #cervicalcancer #highriskCSCC #KEYNOTE630study #CPOSTstudy #Libtayotreatedpatients #PD1PDL1inhibitors
zurl.co/9toKK

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

#Regeneron's PD-1 inhibitor #Libtayo could find wider use for a form of #skincancer known as #cutaneoussquamouscellcarcinoma after showing efficacy in a pivotal trial as adjuvant therapy for patients who have had surgery to remove their tumour.

pharmaphorum.com/news/asco-25...

FDA Approves UNLOXCYT™ from Checkpoint Therapeutics for Advanced Skin Cancer Treatment Checkpoint Therapeutics, Inc. has officially announced a groundbreaking achievement with the U.

www.linkedin.com/pulse/fda-ap...

FDA Approves UNLOXCYT™ from Checkpoint Therapeutics for Advanced Skin Cancer Treatment

kstrategyand.com/pharma-news

#CheckpointTherapeutics #UNLOXCYT #FDAApproval #Immunotherapy #SkinCancer #CutaneousSquamousCellCarcinoma #PDL1Inhibitor #Humanteconomy #Humantec

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - OncoDaily FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma / Andrea Tazbirkova, Andrew Michael Mant,

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
@fda.gov

oncodaily.com/science/fda-...

#Cancer #CutaneousSquamousCellCarcinoma #FDA #OncoDaily #Oncology #Medicine #Health